In 626 virologically suppressed adults with HIV-1, switching to once-weekly oral islatravir-lenacapavir was non-inferior to continuing daily standard of care: HIV-1 RNA ≥50 copies/mL at week 48 in 0·3% vs 1·3%. Treatment-related adverse events 18% vs <1%.
RCTn = 634
Colson et al. Switch to once-weekly, single-tablet islatravir-lenacapavir from daily standard of care for HIV-1 (ISLEND-2): a multicentre, randomised, open-label, active-controlled, phase 3 non-inferiority trial